RxDoctor Payments Data

Amber Fields

Acute Care · Gallipolis, OHNPI 1639629835

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,093in general payments, 2019–2025

Across 245 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$750
  • AbbVie$539
  • Johnson & Johnson$351
  • Takeda Pharmaceuticals U.S.A., Inc.$307
  • Otsuka America Pharmaceutical, Inc.$232
  • AstraZeneca$223
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,95197%
  • Education$1423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,093 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$27,213
Medicare patients
145
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide13$23,956
KerendiaFinerenone13$14,903
FarxigaDapagliflozin Propanediol17$10,747
Potassium Chloride37$435
Amlodipine Besylate59$312
Lisinopril41$256
Calcitriol23$216
Atorvastatin Calcium15$195
Carvedilol28$173
Furosemide64$170
Nifedipine ErNifedipine11$165
Torsemide11$129
Losartan Potassium18$123
Hydralazine Hcl15$115
Metoprolol Tartrate12$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$195$14,90313 claims
AstraZenecaFarxiga$223$10,74717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Gallipolis

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →